Exhibit 99.20
Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions) SECOND QUARTER
Percent Change
2007 2006 Total Operations Currency
Sales to customers by segment
of business
Consumer
U.S. $1,562 $1,103 41.6 % 41.6 -
International 2,002 1,295 54.6 48.1 6.5
3,564 2,398 48.6 45.1 3.5
Pharmaceutical
U.S. 3,860 3,682 4.8 4.8 -
International 2,289 2,128 7.6 2.0 5.6
6,149 5,810 5.8 3.8 2.0
Med Devices & Diagnostics
U.S. 2,619 2,590 1.1 1.1 -
International 2,799 2,565 9.1 4.4 4.7
5,418 5,155 5.1 2.8 2.3
U.S. 8,041 7,375 9.0 9.0 -
International 7,090 5,988 18.4 13.0 5.4
Worldwide $15,131 $13,363 13.2 % 10.8 2.4
(Unaudited; Dollars in Millions) SIX MONTHS
Percent Change
2007 2006 Total Operations Currency
Sales to customers by segment
of business
Consumer
U.S. 3,191 $2,253 41.6 % 41.6 -
International 3,869 2,500 54.8 48.9 5.9
7,060 4,753 48.5 45.4 3.1
Pharmaceutical
U.S. 7,894 7,383 6.9 6.9 -
International 4,476 4,053 10.4 4.7 5.7
12,370 11,436 8.2 6.2 2.0
Med Devices & Diagnostics
U.S. 5,203 5,110 1.8 1.8 -
International 5,535 5,056 9.5 4.6 4.9
10,738 10,166 5.6 3.2 2.4
U.S. 16,288 14,746 10.5 10.5 -
International 13,880 11,609 19.6 14.2 5.4
Worldwide $30,168 $26,355 14.5 % 12.1 2.4
Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions) SECOND QUARTER
Percent Change
2007 2006 Total Operations Currency
Sales to customers by
geographic area
U.S. $8,041 $7,375 9.0 % 9.0 -
Europe 3,907 3,295 18.6 11.0 7.6
Western Hemisphere excluding U.S. 1,131 876 29.1 24.1 5.0
Asia-Pacific, Africa 2,052 1,817 12.9 11.3 1.6
International 7,090 5,988 18.4 13.0 5.4
Worldwide $15,131 $13,363 13.2 % 10.8 2.4
(Unaudited; Dollars in Millions) SIX MONTHS
Percent Change
2007 2006 Total Operations Currency
Sales to customers by
geographic area
U.S. $16,288 $14,746 10.5 % 10.5 -
Europe 7,720 6,366 21.3 13.0 8.3
Western Hemisphere excluding U.S. 2,177 1,698 28.2 25.5 2.7
Asia-Pacific, Africa 3,983 3,545 12.4 10.9 1.5
International 13,880 11,609 19.6 14.2 5.4
Worldwide $30,168 $26,355 14.5 % 12.1 2.4
Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except
Per Share Figures) SECOND QUARTER
2007 2006 Percent
Percent Percent Increase
Amount to Sales Amount to Sales (Decrease)
Sales to customers $15,131 100.0 $13,363 100.0 13.2
Cost of products sold 4,358 28.8 3,788 28.3 15.0
Selling, marketing and
administrative expenses 5,029 33.3 4,351 32.6 15.6
Research expense 1,866 12.3 1,828 13.7 2.1
In-process research &
development (IPR&D) - - 87 0.6
Interest (income)expense, net (36) (0.2) (196) (1.5)
Other (income)expense, net (117) (0.8) (98) (0.7)
Earnings before provision for
taxes on income 4,031 26.6 3,603 27.0 11.9
Provision for taxes on income 950 6.2 783 5.9 21.3
Net earnings $3,081 20.4 $2,820 21.1 9.3
Net earnings per share
(Diluted) $1.05 $0.95 10.5
Average shares outstanding
(Diluted) 2,922.5 2,974.4
Effective tax rate 23.6% 21.7%
Adjusted earnings before
provision for taxes and net
earnings(A)
Earnings before provision
for taxes on income $4,031 26.6 $3,690(1) 27.6 9.2
Net earnings $3,081 20.4 $2,907(1) 21.7 6.0
Net earnings per share
(Diluted) $1.05 $0.98(1) 7.1
Effective tax rate 23.6% 21.2%
(1) The difference between as reported earnings before provision for taxes
on income and net earnings and adjusted earnings before provision for
taxes on income and net earnings is the exclusion of IPR&D of $87
million before tax with no tax benefit, or $0.03 per share.
Johnson & Johnson and Subsidiaries
Supplementary Sales Data
(Unaudited; Dollars in Millions)
SIX MONTHS
2007 2006 Percent Percent Percent
Change Change Change
Total Operations Currency
Sales to customers $30,168 100.0 $26,355 100.0 14.5
Cost of products sold 8,743 29.0 7,400 28.1 18.1
Selling, marketing and
administrative expense 9,831 32.5 8,446 32.0 16.4
Research expense 3,518 11.7 3,360 12.7 4.7
In-process research &
development (IPR&D) 807 2.7 124 0.5
Interest (income)expense,
net (69) (0.2) (377) (1.4)
Other (income)expense, net (345) (1.1) (816) (3.1)
Earnings before provision
for taxes on income 7,683 25.4 8,218 31.2 (6.5)
Provision for taxes on
income 2,029 6.7 2,093 8.0 (3.1)
Net earnings $ 5,654 18.7 $ 6,125 23.2 (7.7)
Net earnings per share
(Diluted) $ 1.93 $ 2.05 (5.9)
Average shares outstanding
(Diluted) 2,924.9 2,982.5
Effective tax rate 26.4 % 25.5 %
Adjusted earnings before
provision for taxes and net
earnings(A)
Earnings before
provision for taxes on
income $ 8,490(1) 28.1 $ 7,720(2) 29.3 10.0
Net earnings $ 6,461(1) 21.4 $ 5,873(2) 22.3 10.0
Net earnings per
share (Diluted) $ 2.21(1) $ 1.97(2) 12.2
Effective tax rate 23.9% 23.9%
(1) The difference between as reported earnings before provision for
taxes on income and net earnings and net earnings per share (diluted)
is IPR&D of $807 million with no tax benefit and $0.28 per share,
respectively.
(2) The difference between as reported earnings before provision for
taxes on income and net earnings and net earnings per share (diluted)
is the Guidant acquisition termination fee of $622 million and $368
million and $0.12 per share, respectively, and IPR&D of $124 million
and $116 million and $0.04 per share, respectively.
(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before
provision for taxes on income," "adjusted net earnings,"
"adjusted net earnings per share (diluted)," and "adjusted
effective tax rate" are non-GAAP financial measures and
should not be considered replacements for GAAP results. The
Company provides earnings before provision for taxes on
income, net earnings, net earnings per share (diluted), and
effective tax rate on an adjusted basis because management
believes that these measures provide useful information to
investors. Among other things, they may assist investors in
evaluating the Company's results of operations period over
period. In various periods, these measures may exclude such
items as business development activities (including IPR&D at
acquisition or upon attainment of milestones and any
extraordinary expenses), strategic developments (including
restructuring and product line changes), significant
litigation, and changes in applicable laws and regulations
(including significant accounting or tax matters). Special
items may be highly variable, difficult to predict, and of a
size that sometimes has substantial impact on the Company's
reported results of operations for a period. Management uses
these measures internally for planning, forecasting and
evaluating the performances of the Company's businesses,
including allocating resources and evaluating results
relative to employee performance compensation targets.
Unlike earnings before provision for taxes on income, net
earnings, net earnings per share (diluted), and effective
tax rate prepared in accordance with GAAP, adjusted earnings
before provision for taxes on income, adjusted net earnings,
adjusted net earnings per share (diluted), and adjusted
effective tax rate may not be comparable with the
calculation of similar measures for other companies. These
non-GAAP financial measures are presented solely to permit
investors to more fully understand how management assesses
the performance of the Company. The limitations of using
these non-GAAP financial measures as performance measures
are that they provide a view of the Company's results of
operations without including all events during a period,
such as the effects of an acquisition, merger-related or
other restructuring charges, or amortization of purchased
intangibles, and do not provide a comparable view of the
Company's performance to other companies in the health care
industry. Investors should consider non-GAAP financial
measures in addition to, and not as replacements for, or
superior to, measures of financial performance prepared in
accordance with GAAP.
Johnson & Johnson
REPORTED SALES vs. PRIOR PERIOD
$MM
CURRENT QUARTER
% Change
--------------------------------
2Q 2Q Reported Operational** Currency
2007 2006
PHARMACEUTICAL SEGMENT*
ACIPHEX/PARIET
US 161 145 10% 10% 0%
Intl 175 163 8% 2% 6%
WW 336 308 9% 6% 3%
Anti-Psychotics(1)
US 653 568 15% 15% 0%
Intl 484 468 3% -2% 5%
WW 1,137 1,036 10% 7% 3%
CONCERTA
US 199 174 14% 14% 0%
Intl 56 43 32% 25% 7%
WW 255 217 18% 16% 2%
DURAGESIC
US 97 121 -20% -20% 0%
Intl 192 215 -11% -15% 4%
WW 289 336 -14% -17% 3%
EPREX/PROCRIT
US 449 524 -14% -14% 0%
Intl 309 284 9% 2% 7%
WW 758 808 -6% -8% 2%
Hormonal Contraceptives
US 175 188 -7% -7% 0%
Intl 65 59 9% 3% 6%
WW 240 247 -3% -4% 1%
LEVAQUIN
US 343 330 4% 4% 0%
Intl 14 10 44% 40% 4%
WW 357 340 5% 5% 0%
REMICADE
US 625 595 5% 5% -
Intl 244 182 34% 34% -
WW 869 777 12% 12% -
TOPAMAX
US 472 393 20% 20% 0%
Intl 106 102 4% -2% 6%
WW 578 495 17% 16% 1%
(1) Includes Risperdal, Risperdal Consta & Invega
YEAR TO DATE
% Change
-------------------------------
2007 2006 Reported Operational** Currency
YTD YTD
PHARMACEUTICAL SEGMENT*
ACIPHEX/PARIET
US 320 291 10% 10% 0%
Intl 352 323 9% 3% 6%
WW 672 614 9% 6% 3%
Anti-Psychotics(1)
US 1,363 1,154 18% 18% 0%
Intl 952 901 6% 0% 6%
WW 2,315 2,055 13% 10% 3%
CONCERTA
US 399 367 9% 9% 0%
Intl 109 85 29% 21% 8%
WW 508 452 12% 11% 1%
DURAGESIC
US 212 231 -8% -8% 0%
Intl 379 430 -11% -16% 5%
WW 591 661 -11% -14% 3%
EPREX/PROCRIT
US 979 1,052 -7% -7% 0%
Intl 596 542 10% 3% 7%
WW 1,575 1,594 -1% -3% 2%
Hormonal Contraceptives
US 350 386 -10% -10% 0%
Intl 127 115 11% 5% 6%
WW 477 501 -5% -6% 1%
LEVAQUIN
US 802 723 11% 11% 0%
Intl 30 20 47% 47% 0%
WW 832 743 12% 12% 0%
REMICADE
US 1,225 1,160 6% 6% -
Intl 375 297 26% 26% -
WW 1,600 1,457 10% 10% -
TOPAMAX
US 973 765 27% 27% 0%
Intl 215 200 8% 2% 6%
WW 1,188 965 23% 22% 1%
(1) Includes Risperdal, Risperdal Consta & Invega
Johnson & Johnson
REPORTED SALES vs. PRIOR PERIOD
$MM
CURRENT QUARTER
% Change
--------------------------------
2Q 2Q Reported Operational** Currency
2007 2006
MEDICAL DEVICES AND
DIAGNOSTICS*
Cordis
US 397 537 -26% -26% 0%
Intl 455 531 -14% -17% 3%
WW 852 1,068 -20% -21% 1%
DePuy
US 663 643 3% 3% 0%
Intl 472 392 21% 14% 7%
WW 1,135 1,035 10% 7% 3%
Ethicon
US 350 321 9% 9% 0%
Intl 551 495 11% 5% 6%
WW 901 816 10% 6% 4%
Ethicon Endo-Surgery
US 454 417 9% 9% 0%
Intl 503 440 14% 9% 5%
WW 957 857 12% 9% 3%
LifeScan
US 310 290 7% 7% 0%
Intl 286 232 23% 16% 7%
WW 596 522 14% 11% 3%
Ortho-Clinical Diagnostics
US 216 185 16% 16% 0%
Intl 190 183 4% 0% 4%
WW 406 368 10% 8% 2%
Total Vision Care
US 213 183 16% 16% 0%
Intl 340 291 17% 17% 0%
WW 553 474 17% 17% 0%
YEAR TO DATE
% Change
-------------------------------
2007 2006 Reported Operational** Currency
YTD YTD
MEDICAL DEVICES AND
DIAGNOSTICS*
Cordis
US 821 1,067 -23% -23% 0%
Intl 959 1,076 -11% -14% 3%
WW 1,780 2,143 -17% -18% 1%
DePuy
US 1,341 1,287 4% 4% 0%
Intl 951 787 21% 14% 7%
WW 2,292 2,074 11% 8% 3%
Ethicon
US 694 617 12% 12% 0%
Intl 1,077 973 11% 5% 6%
WW 1,771 1,590 11% 7% 4%
Ethicon Endo-Surgery
US 871 797 9% 9% 0%
Intl 977 854 14% 9% 5%
WW 1,848 1,651 12% 9% 3%
LifeScan
US 602 578 4% 4% 0%
Intl 543 449 21% 14% 7%
WW 1,145 1,027 12% 9% 3%
Ortho-Clinical Diagnostics
US 434 384 13% 13% 0%
Intl 365 354 3% -2% 5%
WW 799 738 8% 6% 2%
Total Vision Care
US 408 355 15% 15% 0%
Intl 658 560 17% 16% 1%
WW 1,066 915 16.4% 15.2% 0.7%
Johnson & Johnson
REPORTED SALES vs. PRIOR PERIOD
$MM
CURRENT QUARTER
% Change
--------------------------------
2Q 2Q Reported Operational** Currency
2007 2006
CONSUMER SEGMENT* (2)
Skin Care
US 338 281 20% 20% 0%
Intl 419 373 12% 6% 6%
WW 757 654 16% 12% 4%
Baby & Kids Care
US 106 96 10% 10% 0%
Intl 381 325 17% 11% 6%
WW 487 421 16% 11% 5%
Oral Care (3)
US 186 NA - - -
Intl 167 NA - - -
WW 353 NA - - -
OTC/Nutritionals
US 584 414 41% 41% 0%
Intl 622 219 185% 179% 6%
WW 1,206 633 91% 89% 2%
Women's Health
US 164 149 10% 10% 0%
Intl 299 266 12% 5% 7%
WW 463 415 11% 7% 4%
(2) 2007 Includes sales from acquisition of PCH
(3) Oral Care not disclosed in 2006
YEAR TO DATE
% Change
-------------------------------
2007 2006 Reported Operational** Currency
YTD YTD
CONSUMER SEGMENT* (2)
Skin Care
US 695 598 16% 16% 0%
Intl 826 715 16% 10% 6%
WW 1,521 1,313 16% 13% 3%
Baby & Kids Care
US 215 199 8% 8% 0%
Intl 719 628 15% 9% 6%
WW 934 827 13% 9% 4%
Oral Care (3)
US 389 NA - - -
Intl 324 NA - - -
WW 713 NA - - -
OTC/Nutritionals
US 1,239 859 44% 44% 0%
Intl 1,224 427 187% 181% 6%
WW 2,463 1,286 91% 89% 2%
Women's Health
US 326 297 10% 10% 0%
Intl 558 517 8% 2% 6%
WW 884 814 9% 5% 4%
(2) 2007 Includes sales from acquisition of PCH
(3) Oral Care not disclosed in 2006
* Selected Areas (Unaudited)
** Operational growth excludes the effect of currency